Current Report Filing (8-k)
November 12 2019 - 5:22PM
Edgar (US Regulatory)
0000885725
false
DE
0000885725
2019-11-06
2019-11-06
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event
reported): November 6, 2019
BOSTON SCIENTIFIC CORPORATION
(Exact name of registrant as specified in its
charter)
|
|
|
|
|
DELAWARE
|
|
1-11083
|
|
04-2695240
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
300 Boston Scientific Way, Marlborough, Massachusetts
|
|
01752-1234
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s
telephone number, including area code: (508) 683-4000
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of
each class
|
Trading
Symbol
|
Name of
each exchange on which registered
|
Common Stock, $0.01 par value per share
|
BSX
|
New York Stock Exchange
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ¨
ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT
On November 6, 2019, Boston Scientific Corporation (the “Company”)
entered into an Underwriting Agreement, (as supplemented by the Terms Agreement, also dated November 6, 2019, the “Underwriting
Agreement”), among the Company and Barclays Bank PLC, Merrill Lynch International and Goldman Sachs & Co. LLC, as representatives
of the underwriters named in the Underwriting Agreement (the “Underwriters”), in connection with the Company’s
previously announced pricing of €900,000,000 aggregate principal amount of senior notes. Pursuant to the Underwriting Agreement,
the Underwriters agreed to purchase €900,000,000 in aggregate principal amount of the Company’s 0.625% Senior Notes
due 2027 (the “Notes”) under the Company’s shelf registration statement on Form S-3 (File No. 333-223095). The
Underwriting Agreement contains customary representations, warranties and agreements of the Company and customary conditions to
closing, indemnification rights and obligations of the parties and termination provisions. The Underwriters and their affiliates
have performed commercial banking, investment banking and advisory services for the Company from time to time for which they have
received customary fees and expenses. The Underwriters and their affiliates may, from time to time, engage in transactions with
and perform services for the Company in the ordinary course of their business.
The Notes were issued pursuant to an indenture
dated as of May 29, 2013 between the Company and U.S. Bank National Association, as trustee (the “Indenture”). The
Indenture contains covenants that restrict the Company’s ability, with certain exceptions, to (i) merge or consolidate with
another entity or transfer all or substantially all of its property and assets, and (ii) incur liens. These covenants are subject
to important exceptions and qualifications, as described in the Indenture. The Indenture also provides for customary events of
default. Additional terms of the Notes are set forth in the form of notes attached hereto as Exhibit 4.2.
The foregoing descriptions of the Underwriting
Agreement, the Indenture and the Notes are summaries and are qualified in their entirety by reference to such documents, which
are attached as Exhibits 1.1, 4.1 and 4.2 to this Current Report on Form 8-K, respectively, and all of which are incorporated herein
by reference.
ITEM 8.01 OTHER EVENTS
On November 12, 2019, the Company completed
the offering of the Notes. The net proceeds from the offering of the Notes, after deducting the underwriting discount and estimated
offering expenses, were approximately €887 million. The Company used the net proceeds from the offering of the Notes to (i)
fund the previously announced tender offer for up to $1.0 billion in aggregate principal amount of certain series of the Company’s
senior notes (the “Tender Offer”), and (ii) pay accrued and unpaid interest, premiums, fees and expenses in connection
with the Tender Offer.
On November 12, 2019, the early settlement
date of the Tender Offer, the Company completed the Tender Offer, pursuant to which it accepted $206,429,000, $566,455,000, and
$227,117,000 of tendered principal amounts of its 4.125% Senior Notes due 2023, 4.000% Senior Notes due 2028 and 3.850% Senior
Notes due 2025, respectively.
In connection with the offering of the Notes,
the Company is filing a legal opinion regarding the validity of the Notes, attached as Exhibit 5.1 to this Current Report on Form
8-K.
Additionally, on November 12, 2019, the Company
issued a press release pertaining to the events described in this Current Report
on Form 8-K, a copy of which is attached as Exhibit 99.1 hereto and is hereby incorporated
by reference herein.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibits
Exhibit
No.
|
|
|
|
|
|
1.1*
|
|
Underwriting Agreement, dated as of November 6, 2019, as supplemented by the Terms Agreement, dated November 6, 2019, among Boston Scientific Corporation and Barclays Bank PLC, Merrill Lynch International and Goldman Sachs & Co. LLC, as representatives of the underwriters.
|
4.1
|
|
Indenture dated as of May 29, 2013, between Boston Scientific Corporation and U.S. Bank National Association, as trustee (filed as Exhibit 4.1 to the Company’s Registration Statement on Form S-3, filed on May 29, 2013 and incorporated herein by reference).
|
4.2*
|
|
Form of 0.625% Senior Note due 2027.
|
5.1*
|
|
Opinion dated November 12, 2019 of Shearman & Sterling LLP.
|
23.1*
|
|
Consent of Shearman & Sterling LLP (included in Exhibit 5.1).
|
99.1*
|
|
Press Release issued by Boston Scientific Corporation, dated November 12, 2019.
|
104
|
|
Cover Page Interactive Data File (embedded within the Inline XBRL document).
|
* Documents filed or furnished with this report.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act
of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
BOSTON SCIENTIFIC CORPORATION
|
|
|
|
|
Date: November 12, 2019
|
|
|
|
By:
|
|
/s/ Vance R. Brown
|
|
|
|
|
|
|
Vance R. Brown
Vice President and Chief Corporate Counsel
|
|
|
|
|
|
|
|
Boston Scientific (NYSE:BSX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Boston Scientific (NYSE:BSX)
Historical Stock Chart
From Apr 2023 to Apr 2024